Who Pays My Doctor?

Healthcare provider profile · identity verified

Kostas N Botsoglou, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · CHEEKTOWAGA, NY · NPI 1295981652

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kostas N Botsoglou, M.D. received $519,089.54 in general payments during 2025 across 786 reported records.

ABBVIE INC. accounted for 23.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 32 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Otezla, Prolia, Rinvoq, Xeljanz.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Rinvoq by this doctor in 2024.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xeljanz by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$519,089.54

786 reported records · 23 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $123,451.2823.8%1432025
Mallinckrodt Hospital Products Inc. Unresolved — no canonical attribution shown $103,513.9219.9%1312025
UCB, Inc. Unresolved — no canonical attribution shown $69,147.3913.3%1112025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $48,901.929.4%772025
ANI Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $47,449.029.1%762025
Amgen Inc. Unresolved — no canonical attribution shown $44,818.308.6%672025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $38,390.427.4%572025
GENZYME CORPORATION Unresolved — no canonical attribution shown $18,282.393.5%202025
KYOWA KIRIN, INC. Unresolved — no canonical attribution shown $13,992.412.7%222025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $7,537.501.4%172025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $1,725.080.3%92025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $496.230.1%42025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $351.470.1%42025
PFIZER INC. Unresolved — no canonical attribution shown $304.980.1%242025
Alexion Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $226.920.0%102025
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $219.800.0%22025
Aurinia Pharma U.S., Inc. Unresolved — no canonical attribution shown $72.670.0%32025
Genentech USA, Inc. Unresolved — no canonical attribution shown $64.380.0%22025
Sandoz Inc. Unresolved — no canonical attribution shown $52.630.0%32025
Fresenius Kabi USA, LLC Unresolved — no canonical attribution shown $26.970.0%12025
Actelion Pharmaceuticals US, Inc. Unresolved — no canonical attribution shown $25.480.0%12025
Invivyd Inc Unresolved — no canonical attribution shown $24.800.0%12025
SCILEX PHARMACEUTICALS INC. Unresolved — no canonical attribution shown $13.580.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$365,670.50114
Travel and Lodging$73,850.17275
Honoraria$35,487.5015
Consulting Fee$24,487.507
Food and Beverage$19,593.87375

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
ACTHAR
Normalized: acthar		 Biological Mallinckrodt Hospital Products Inc. $103,513.92 131 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $69,147.39 111 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $68,342.74 90 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc., Janssen Scientific Affairs, LLC $49,398.15 81 2025
Source payment records
SIMPONI ARIA
Normalized: simponi aria		 Biological Janssen Biotech, Inc. $47,989.21 63 2025
Source payment records
PURIFIED CORTROPHIN GEL
Normalized: purified cortrophin gel		 Drug ANI Pharmaceuticals, Inc. $47,449.02 76 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $42,023.02 43 2025
Source payment records
SAPHNELO
Normalized: saphnelo		 Biological AstraZeneca Pharmaceuticals LP $38,274.61 56 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $26,999.24 34 2025
Source payment records
KEVZARA
Normalized: kevzara		 Biological GENZYME CORPORATION $18,282.39 20 2025
Source payment records
TAVNEOS
Normalized: tavneos		 Drug Amgen Inc. $17,313.53 26 2025
Source payment records
CRYSVITA
Normalized: crysvita		 Drug KYOWA KIRIN, INC. $7,856.63 18 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $479.11 4 2025
Source payment records
KRYSTEXXA
Normalized: krystexxa		 Biological Amgen Inc. $350.21 3 2025
Source payment records
XELJANZ
Normalized: xeljanz		 Drug PFIZER INC. $304.98 24 2025
Source payment records
STRENSIQ
Normalized: strensiq		 Biological Alexion Pharmaceuticals, Inc. $226.92 10 2025
Source payment records
BENLYSTA
Normalized: benlysta		 Biological GlaxoSmithKline, LLC. $219.80 2 2025
Source payment records
EVENITY
Normalized: evenity		 Biological Amgen Inc. $149.88 3 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $142.55 2 2025
Source payment records
ORENCIA
Normalized: orencia		 Biological E.R. Squibb & Sons, L.L.C. $90.92 4 2025
Source payment records
LUPKYNIS
Normalized: lupkynis		 Drug Aurinia Pharma U.S., Inc. $72.67 3 2025
Source payment records
Gazyva
Normalized: gazyva		 Biological Genentech USA, Inc. $64.38 2 2025
Source payment records
HYRIMOZ
Normalized: hyrimoz		 Biological Sandoz Inc. $38.35 2 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $34.15 2 2025
Source payment records
ENBREL
Normalized: enbrel		 Biological Amgen Inc. $32.10 2 2025
Source payment records
PROLIA
Normalized: prolia		 Biological Amgen Inc. $31.19 2 2025
Source payment records
OPSUMIT
Normalized: opsumit		 Drug Actelion Pharmaceuticals US, Inc. $25.48 1 2025
Source payment records
UPTRAVI
Normalized: uptravi		 Drug Actelion Pharmaceuticals US, Inc. $25.48 1 2025
Source payment records
PEMGARDA
Normalized: pemgarda		 Biological Invivyd Inc $24.80 1 2025
Source payment records
JUBBONTI
Normalized: jubbonti		 Biological Sandoz Inc. $14.28 1 2025
Source payment records
GLOPERBA
Normalized: gloperba		 Drug SCILEX PHARMACEUTICALS INC. $13.58 1 2025
Source payment records
UPLIZNA
Normalized: uplizna		 Biological Amgen Inc. $5.44 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ENBREL
enbrel		 2025 Enbrel 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
OTEZLA
otezla		 2025 Otezla 2024 13
Beneficiary count suppressed		 exact normalized Medicare Part D
PROLIA
prolia		 2025 Prolia 2024 23 exact normalized Medicare Part D
RINVOQ
rinvoq		 2025 Rinvoq 2024 120 exact normalized Medicare Part D
XELJANZ
xeljanz		 2025 Xeljanz 2024 21
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 RINVOQ
open payments reported associated product		 CMS Open Payments — General Payments
279238 supporting records · 34343 recipient NPIs · example record 1201352600 		Rinvoq · 2024
Exact normalized brand match · 1 Part D row		 120 20
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 ENBREL
open payments reported associated product		 CMS Open Payments — General Payments
9330 supporting records · 2094 recipient NPIs · example record 1226877474 		Enbrel · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 OTEZLA
open payments reported associated product		 CMS Open Payments — General Payments
177267 supporting records · 48600 recipient NPIs · example record 1226871616 		Otezla · 2024
Exact normalized brand match · 1 Part D row		 13 suppressed by CMS
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 PROLIA
open payments reported associated product		 CMS Open Payments — General Payments
20867 supporting records · 11744 recipient NPIs · example record 1226874448 		Prolia · 2024
Exact normalized brand match · 1 Part D row		 23 14
PFIZER INC.
Exact reporting entity; no affiliate inference		 2025 XELJANZ
open payments reported associated product		 CMS Open Payments — General Payments
32588 supporting records · 8614 recipient NPIs · example record 1228794176 		Xeljanz · 2024
Exact normalized brand match · 1 Part D row		 21 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Hydroxychloroquine SulfateHydroxychloroquine Sulfate408153
MethotrexateMethotrexate Sodium388141
PrednisonePrednisone22082
Folic AcidFolic Acid15657
RinvoqUpadacitinib12020
Enbrel SureclickEtanercept9212
GabapentinGabapentin8321
ColchicineColchicine6211
AzathioprineAzathioprine5323
MethylprednisoloneMethylprednisolone4613
AllopurinolAllopurinol4113
Humira(Cf) PenAdalimumab41suppressed
Xeljanz XrTofacitinib Citrate30suppressed
Sulfasalazine DrSulfasalazine2913
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz28suppressed
LeflunomideLeflunomide25suppressed
Alendronate SodiumAlendronate Sodium23suppressed
Diclofenac SodiumDiclofenac Sodium23suppressed
Orencia ClickjectAbatacept23suppressed
ProliaDenosumab2314
FebuxostatFebuxostat21suppressed
XeljanzTofacitinib Citrate21suppressed
CelecoxibCelecoxib20suppressed
SulfasalazineSulfasalazine15suppressed
Mycophenolate MofetilMycophenolate Mofetil14suppressed
Nifedipine ErNifedipine14suppressed
PregabalinPregabalin14suppressed
InflectraInfliximab-Dyyb13suppressed
OtezlaApremilast13suppressed
EnbrelEtanercept12suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $519,089.54 · 786 records ABBVIE INC. ACTHAR, BENLYSTA, Bimzelx, COSENTYX, CRYSVITA, ENBREL, EVENITY, GLOPERBA, Gazyva, HYRIMOZ, JUBBONTI, KEVZARA, KRYSTEXXA, LUPKYNIS, OPSUMIT, ORENCIA, OTEZLA, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, SPEVIGO, STRENSIQ, Sotyktu, TAVNEOS, TREMFYA, UPLIZNA, UPTRAVI, XELJANZ 5 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error